DNA Breast 360 - Breast Cancer Screening & Reports
- Regular price
- Sale price
- Regular price
Description
Description
Think breast cancer screening is only for older women or requires a trip to the clinic? Think again—DNA Breast 360 changes the game, offering a groundbreaking, non-invasive way to detect early signs of breast cancer from the comfort of home.
-
Collect your sample easily and painlessly at home using a simple tear strip.
-
Detects advanced biomarkers linked to inflammation and cancer for powerful health insights.
-
An accessible option for women under 50, those in areas without traditional screenings, and those with dense breast tissue.
-
Offers 92% sensitivity to catch breast cancer early when it’s most treatable.
-
Works alongside mammograms to give you extra confidence in monitoring your breast health.
-
DNA Breast 360 helps women take charge of their health with a test that’s innovative, easy, and life-changing.
- A free clinician appointment with any positive result to create a healthcare gameplan.
Couldn't load pickup availability
Early Detection is The Key to Better Outcomes
Early detection of breast cancer dramatically improves treatment options and potential outcomes. According to the American Cancer Society, when breast cancer is caught early (at a localized stage), the 5-year survival rate is 99%. In contrast, this drops to 29% when the cancer has spread to distant areas. By utilizing advanced screening tools like DNA Breast 360, you gain an extra layer of insight into your breast health, allowing for earlier detection of potential issues and giving you the best chance at successful treatment.
Proactive Breast Cancer Screening for a Healthier Future
Early detection of breast cancer is a vital step in taking control of your health and well-being. With the DNA Breast 360, you can identify potential risks at an earlier stage, giving you a crucial advantage in treatment options. Early screening not only increases the likelihood of successful outcomes but also offers peace of mind, knowing you’ve taken a proactive step toward protecting your future. By catching warning signs early, you’re empowering yourself with more choices and greater control over your breast health journey.
Future-Proof Your Health with DNA Breast 360
Making DNA Breast 360 part of your annual health routine empowers you with the knowledge and foresight to stay ahead of potential health risks. This innovative test gives you the advantage of early detection, helping you identify cancer-related activity before it becomes critical. By integrating this simple, non-invasive screening into your regular wellness checkup, you’re not just safeguarding your future—you’re giving yourself the gift of time, ensuring that any potential issues can be addressed early, when treatment is most effective. Future-proof your health and take control with DNA Breast 360.
FAQs
What is DNA Breast 360?
DNA Breast 360 is an innovative, non-invasive breast cancer screening test that analyzes specific proteins in your tears to detect early signs of breast cancer. It’s designed to be used alongside traditional screening methods like mammography, providing an additional layer of insight into your breast health.
How does DNA Breast 360 work?
The test uses a simple tear sample collected with a Schirmer strip placed inside your lower eyelid. The strip absorbs your tears, which are then analyzed in a lab for specific protein biomarkers linked to breast cancer.
Why are tears used instead of blood?
Tears are used because they provide a cleaner sample for detecting cancer-related proteins. Blood contains large components like red blood cells, white blood cells, and large proteins that can obscure small but critical markers of disease, making detection less precise. In contrast, tears are free from these larger elements, allowing for more accurate and reliable identification of cancer biomarkers.
What proteins does DNA Breast 360 test for?
DNA Breast 360 measures two key proteins in your tears:
- S100A8 (Calgranulin A) and S100A9 (Calgranulin B): These proteins are involved in the body’s inflammatory response and are frequently elevated in breast cancer. They play a role in tumor growth and metastasis, making them essential markers for early cancer detection.
Who should use DNA Breast 360?
DNA Breast 360 is suitable for all women aged 30 and older who want to monitor their breast health, especially those who might not have easy access to mammography, those under 50 who are not routinely screened, or those in rural or underserved areas.
How often should I get tested with DNA Breast 360?
It is recommended to take the DNA Breast 360 test annually, particularly if you are in a higher risk category or as advised by your healthcare provider. Regular testing helps track changes over time and ensures that any early signs of breast cancer are detected promptly.
Is DNA Breast 360 a replacement for mammograms?
No, DNA Breast 360 is not a replacement for mammograms. It is designed to complement traditional screening methods, providing additional information about your breast health, particularly for younger women and those who may face barriers to regular imaging.
How accurate is DNA Breast 360?
Clinical studies have shown that DNA Breast 360 has a sensitivity of 92% for detecting clinically significant activity related to breast cancer. This means it is highly effective at identifying potential issues that need further investigation.
What do the test results mean?
Results are classified as either Positive (Clinically Significant) or Negative (Not Clinically Significant). A Positive result suggests elevated inflammatory or cancer-related activity, and follow-up imaging, such as a mammogram, is recommended. A Negative result indicates no significant findings, but you should continue with routine breast screenings.
Is the test painful or uncomfortable?
The tear collection process is simple and non-invasive. The Schirmer strip is placed gently in your lower eyelid for a few minutes, and most patients experience only mild discomfort, similar to a brief eye exam.
Is this test valid for men or people undergoing gender-affirming care?
This test is currently designed for individuals who were assigned female at birth, as it has been specifically validated for this group. Currently, we do not have sufficient data to ensure accuracy for men or individuals undergoing gender-affirming hormonal therapies, but we are actively working to expand our research in the future.
Does my collection kit expire?
Yes, the preservation fluid inside the collection device expires, depending on the kit type, it is viable for 12-18 months. If you have an unused collection kit and you are unsure if you need a replacement, please check the date of your order or contact clientcare@thednacompany.com
How we’ve changed lives
“I have never heard about this test so really didn't know what to expect. After receiving the box, the instructions that came with it were very clear. I like that you could watch the video that showed you exactly how to proceed with the test. The process was explained very well...My results came in a few days later. They were thorough and clear.”
Pauline R.
“I am really impressed with this kit. It has everything that I need, and even includes some extra supplies in case you chicken out. The eye drop swatch is not the most comfortable test, but it's better than a blood draw in my opinion.”
Rebecca S.
“Using DNA Breast 360 for cancer screening is really convenient as my insurance does not cover mammograms until the age of 40. I understand this is not for diagnosis purposes, but it will give me peace of mind in the mean time. The box has everything you may need to collect and ship the sample.”
Naya M.
“As soon as my DNA Breast 360 box arrived I opened it. The instructions were clear and it was very well packaged. I actually have an eye condition where my corneas are easily scratched and this didn't bother me at all. Collection was simple and while it was a little irritating for my eye, it didn't last long. Packaging it up was a breeze. I took it to my nearest shipping store and it was on its way the same day.”
Alma N.